Purple Biotech (PPBT)

• Market cap: $4.71M
• 1 day: 3%
• 5 days: -10.16%
• 1 month: -19.63%
• 3 months: -34.9%
• 6 months: -76.42%
• Year to date: -21.09%
• 1 year: -82.28%
• 5 years: -99.46%
• 10 years: -99.9%
• Sector: Healthcare
• Industry: Biotechnology

About: Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Employees: 7